|
|
|
|
|
|
|
|
Commercial Programs:
is a blood test designed to identify patients afflicted with Alzheimer’s disease. Proof of concept is recognized in the peer-reviewed literature (Kim, D.K. et al., Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacology. 25(1):84-90, 2001). The Company is developing this product with the assistance of UK based Fleet BioProcessing. more...
is a carrier for delivery of therapeutic agents across the BBB. biOasis has performed proof of concept studies for Transcend™ and has demonstrated the delivery of drugs across the BBB (Karkan, D. et al. 2008 A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier. PLoS ONE 3(6): e2469.doi:10.1371/journal.pone.0002469). By commercializing Transcend™ biOasis will enable the routine treatment of a variety of clinically challenging CNS conditions. To reduce commercial risk and decrease time to regulatory approval, our initial focus is on linking Transcend™ to drugs that have already been approved by regulatory agencies for non-CNS indications. Our business strategy for Transcend also includes the delivery of novel biologics (proteins & peptides) to treat CNS diseases for which there are limited therapeutic option.. The biOasis business model is based on the aggressive out-licensing of Transcend™ to ensure broad use within the industry. |
|
|
|
| |
|
|
|
| © 2010 bIOasis Technologies Inc. All Rights Reserved
|
|